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Omalizumab has been investigated in various other con-
ditions including chronic urticaria (CU), perennial and
seasonal allergic rhinitis (AR), pruritic bullous pemphi-
goid, latex allergy, peanut allergy, idiopathic anaphylaxis,
hyper-IgE syndrome, chronic rhinosinusitis, interstitial
cystitis, aspirin sensitivity, mastocytosis, eosinophilic
gastroenteritis and atopic dermatitis. Most patients with
chronic urticaria have an autoimmune cause: some
patients produce IgE autoantibodies against autoanti-
gens, such as thyroperoxidase or doublestranded DNA,
whereas other patients make IgG autoantibodies against
FcεRI, IgE, or both, which might chronically activate
mast cells and basophils.I had a male patients with food
allergy with pulmonary carsinoid tumor, aged 23. Auto-
logous Serum Skin Test, Anti Nuclear Antibody,and
hepatitis markers (HBsAg, HBsAb, anti HCV HIV, thyr-
oid antibodies were negative in patients. Liver, thyroid,
and renal function tests, serum IgG, IgA, IgM, levels
were within normal ranges. Skin prick tests (SPTs) were
highly positive for kiwi, tometo, fish, orange The specific
IgE levels were correlated with the SPTs. Total IgE level
were 960 IU/L (normal range:0-100 IU/L).A mass was
defined on lober lobe of left lung on computerized
tomography. PET CT SUVmax:6. The patient was oper-
ated. In postoperative period, he had recurrent laryngeal
oedema and urticaria attacks. Omalizumab treatment
planned because of the patient was resistant to antihista-
minics and steroids.
For the very first time, we used omalizumab in symp-
tomatic therapy of recurrent laryngeal oedema and urti-
caria attacts in a patient with post operative pulmonary
carsinoid tumor for eight months. During the four years
of follow-up, no reccurrens was noted in carsinoid
tumor. Control PET CT and CT results revealed normal
findings.After omalizumab treatment, symptoms were
decreased. Oral antihistaminics and mast cell stabilizing
drugs used for treatment afterwards. Oral steroid was
given only once.
Resent sutudies show that, Pooled data analysis
revealed that a causal relationship between omalizumab
therapy and malignancy is unlikely.
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